$160 - $200M or $2.90 to $3.60 per share is their valuation!!!
"We believe that Invex is undervalued and post a successful trial result the company should trade at a
valuation of $160m to $200m (which is a share price of $2.90 to $3.60 per share on current issued
capital). We believe that as the company de-risks further there is upside to this valuation which may
be realised through a commercial transaction with a pharma company."
http://invextherapeutics.com/wp-content/uploads/2020/03/March-FiftyOne-Capital-Report-.pdf
FiftyOne Capital Report $2.90 to $3.60 per share
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.087M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 219915 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 7950 | 1 |
View Market Depth
| Last trade - 10.04am 10/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable